Walgreens: Ridiculously Cheap at Current Levels


Just over a week ago, I highlighted several stocks I thought looked attractive based on their valuations and dividend yields relative to their historical averages.

Of these names, Walgreens Boots Alliance (NASDAQ:WBA) was trading the furthest below its 10-year average valuation. The stock also offers a 4%+ dividend yield at the moment, which is nearly double the stock's average yield since 2010. A year-to-date share price decline of 28% has aided in realizing these figures.

Quarterly highlights


While I've already stated I am interested in the stock because of its valuation and dividend, Walgreens' most recent quarter was solid. Revenue grew 3.7% to $35.8 billion for the second quarter of fiscal 2020, beating analysts' estimates by $575 million. Excluding the impact of currency translation, revenue was higher by 4.1%. Adjusted earnings per share decreased 7.3% to $1.52, though this was 6 cents higher than Wall Street analysts were looking for. Earnings declined mostly due to a challenging retail market in the UK.

The Retail Pharmacy U.S. segment had sales growth of 3.8% to $27.2 billion. Comparable same-store sales for locations opened at least one year were higher by 2.7%. Pharmacy sales were up 5.3%, with comparable sales growing 3.7%. The total number of prescriptions filled reached 296.8 million, 3.7% higher than the previous year. Even with this growth, prescription market share decreased 50 basis points to 21%. Still, Walgreens' prescription market share is second only to CVS Health Corporation (NYSE:CVS), which means the company is still a dominant player in the U.S. market.





Retail Pharmacy U.S.'s retail business had a sales decline of 0.3%, but, excluding tobacco sales, improved 1.9%. Overall, comparable sales were up 0.6%. Strong demand in Health & Wellness due to cold, cough and flu season aided results.



Comments